Dr. Brad Bolzon, Phd
Board of Directors
okairos
Italy
Biography
Brad also serves as Chairman on the boards of Inception, Amira, Euroventures - a wholly owned biotech incubator within Versant Ventures – and Vice-Chairman of Biotie Therapies. In addition, he is a board member of QC Pharma, Ananaphore, Metabolex, Flexion Therapeutics, Metabolex and Versense Pharmaceuticals. Brad previously served on the board of directors of Speedel, which was acquired by Novartis in July 2008. Previously, Brad served as Executive Vice President and Global Head of Business Development, Licensing & Alliances at Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened the company’s product pipeline. Brad has also held executive roles at Eli Lilly in drug discovery, business development, clinical research and regulatory affairs. Brad received PhD and MSc degrees in Pharmacology from the University of Toronto, and conducted his post-doctoral research training at the Ottawa Heart Institute in Ottawa, Canada.
Research Interest
business
